U.S. Offers New HTLV-1 Vaccine Technology for Licensing
Published Date: 7/2/2026
Notice
Summary
The National Cancer Institute has created a new vaccine to stop HTLV-1, a virus that can cause serious diseases like leukemia. Right now, no vaccine exists, so this invention could protect millions, especially in underserved areas. They’re looking for partners to help develop and license this promising vaccine, which could save lives and reduce healthcare costs in the near future.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Potential HTLV-1 Vaccine Could Cut Disease Burden
The invention is a preventive nucleic acid-based vaccine that produces HTLV-1 virus-like particles and is intended to protect against HTLV-1 infection, which is linked to adult T-cell leukemia/lymphoma (ATLL) and HAM/TSP. The notice states this vaccine could protect millions—particularly in underserved global regions—and reduce healthcare costs and the economic burden of treating related diseases; it is currently being tested in non-human primates.
Government Vaccine Licensing Opportunity
The National Cancer Institute is seeking research co-development partners and/or licensees for a nucleic acid-based chimeric virus-like particle (VLP) vaccine to prevent HTLV-1 infection (NIH Reference Number E-126-2022). The technology is at the preclinical (in vivo validation) stage and is available for licensing and commercial development.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13480 — Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.
2026-13244 — The Federal Demonstration Partnership; Phase VIII Notice
The Federal Demonstration Partnership (FDP) is inviting colleges, universities, research groups, and hospitals that get federal research money to join its Phase VIII starting in 2027. This phase will keep testing new ways to make research funding and rules easier and faster. Applications are due by September 15, 2026, with the program running through the end of 2032.
2026-13311 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review grant applications and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants or contracts should watch these dates closely, as funding decisions could impact their projects and budgets.
2026-13337 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on July 24, 2026, to review and evaluate important grant applications related to cancer, imaging, eye diseases, and reproductive health. These meetings protect private info and trade secrets, so they’re not open to the public. Researchers and organizations applying for grants should note the dates as these reviews impact funding decisions.
2026-13204 — Proposed Collection; 30-Day Comment Request; NIH Information Collection Forms to Support the Genetic Testing Registry (OD)
The NIH wants your thoughts on updating forms that help track genetic tests in their registry. If you’re involved in genetic testing or research, these changes could affect how you share info. You’ve got until July 30, 2026, to send in your comments—no cost, just your voice to help make things smoother and smarter!
2026-12843 — Government Owned Inventions Available for License: C8166-45 Cell Line
The National Cancer Institute is offering a special human T-cell line called C8166-45 for licensing. This cell line helps scientists study viruses like HTLV-1 and HIV, which can cause serious diseases. Researchers and companies can now use this tool to develop better treatments, with licensing info available starting June 2026—no patents, just pure science power ready to roll!
Previous / Next Documents
Previous: 2026-13478 — Agency Information Collection Activities: Request for Comments; Revision of Currently Approved Information Collection(s): U.S. Department of Transportation, Individual Complaint of Employment Discrimination Form
The U.S. Department of Transportation is updating its form for people to report job discrimination. This affects current and former DOT employees or job applicants who want to file a complaint. The form takes about an hour to fill out, and the DOT is asking for comments by August 2, 2026, before finalizing the update—no big cost changes expected.
Next: 2026-13480 — Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.